logo

MIRM

Mirum·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

MIRM fundamentals

Mirum (MIRM) released its earnings on Nov 4, 2025: revenue was 133.01M (YoY +47.17%), beat estimates; EPS was 0.05 (YoY +116.67%), beat estimates.
Revenue / YoY
133.01M
+47.17%
EPS / YoY
0.05
+116.67%
Report date
Nov 4, 2025
MIRM Earnings Call Summary for Q3,2025
  • Revenue Growth: Q3 2025 revenue of $133 million (+47% YoY), driven by LIVMARLI U.S. expansion and international growth.
  • Pipeline Momentum: VISTAS PSC Phase IIb study fully enrolled; interim data supports volixibat efficacy in PSC.
  • Financial Health: GAAP net income of $3 million, cash balance of $378 million, and updated 2025 guidance of $500-510 million.
  • Strategic Focus: Rare disease leadership with three $1B+ pipeline candidates (LIVMARLI, volixibat, MRM-3379).
EPS
Revenue

Revenue & Expenses

MIRM has released its 2025 Q3 earnings report, with revenue of 133.01M, reflecting a YoY change of 47.17%, and net profit of 2.90M, showing a YoY change of 120.41%. The Sankey diagram below clearly presents MIRM's revenue sources and cost distribution.

Key Indicators

Mirum (MIRM) key financial stats and ratios, covering profitability, financial health, and leverage.
Mirum (MIRM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Mirum (MIRM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Mirum (MIRM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Mirum (MIRM) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Mirum (MIRM) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield